Hunter C Smith sold $6.6M of RYTM
Chief Financial Officer at RHYTHM PHARMACEUTICALS, INC.. 62,774 shares at an average of $105.46, traded Aug 31, 2026, filed Sep 1, 2026.
Score components
- +22RoleCFO
- +25Trade size$6.6M at market
- +10Share of holdings soldSold 36% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001649904-26-000023, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | MOption exercise Common Stock10b5-1 | +57,187 | $25.79 | $1.5M | 176,798 | 41 d ago |
| Aug 31, 2026 | SOpen-market sale Common Stock10b5-1 | -23,072 | $104.59 | $2.4M | 153,726 | 41 d ago |
| Aug 31, 2026 | SOpen-market sale Common Stock10b5-1 | -11,514 | $105.37 | $1.2M | 142,212 | 41 d ago |
| Aug 31, 2026 | SOpen-market sale Common Stock10b5-1 | -28,188 | $106.20 | $3.0M | 114,024 | 41 d ago |
| Aug 31, 2026 | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -57,187 | $0.00 | $0 | 3,813 | 41 d ago |
Related signals
Other insiders at RHYTHM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | RHYTHM PHARMACEUTICALS, INC. | David P Meeker President and CEO | $5.1M 50,000 shares | -17% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $372k 3,350 shares | -14% | |
| 0Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $352k 3,350 shares | -14% | |
| 25Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $2.3M 22,866 shares | -57% | |
| 25Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $1.8M 16,781 shares | -66% | |
| 21Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $419k 4,188 shares | -33% | |
| 26Weak | RHYTHM PHARMACEUTICALS, INC. | Christopher Paul German Corporate Controller & CAO | $143k 1,500 shares | -62% | |
| 32Weak | RHYTHM PHARMACEUTICALS, INC. | Hunter C Smith Chief Financial Officer | $2.7M 28,088 shares | -20% | |
| 20Weak | RHYTHM PHARMACEUTICALS, INC. | Joseph Shulman Chief Technical Officer | $359k 3,984 shares | -32% | |
| 6Weak | RHYTHM PHARMACEUTICALS, INC. | Pamela J. Cramer Chief Human Resources Officer | $131k 1,520 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.